Cancer Treatment, Testing & Research

Own the cancer-care chain through established oncology medicines, molecular testing and laboratory tools rather than a single experimental treatment. Diversified drugmakers anchor the basket, while specialist diagnostic businesses provide more direct exposure to precision oncology. With market breadth soft and chip leadership uneven, this offers a distinct healthcare allocation tied to treatment demand and research activity; clinical setbacks, reimbursement pressure and research-budget weakness remain risks. Launch basket (equal weight): MRK, ABBV, AMGN, LLY, TMO, NTRA, GH Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.